The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
<i>Aza</i>-Quasi-Favorskii Reaction: Construction of Highly Substituted Aziridines through a Concerted Multibond Rearrangement Process
作者:Padmanabha V. Kattamuri、Jidong Zhao、Tamal Kanti Das、Juha H. Siitonen、Nathan Morgan、Daniel H. Ess、László Kürti
DOI:10.1021/jacs.2c03805
日期:2022.6.22
A new molecular rearrangement, the aza-Quasi-Favorskii rearrangement, has been developed for the construction of highly substituted aziridines. Electron-deficient O-sulfonyl oximes react readily with α,α-disubstituted acetophenone-derived enolates to furnish highly substituted aziridines via this unprecedented domino process. In-depth computational studies reveal an asynchronous yet concerted nitrenoid-type
[EN] OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS<br/>[FR] INHIBITEURS D'OXAZINE MO NO AC YLG LYCE RO L LIPASE (MAGL)
申请人:HOFFMANN LA ROCHE
公开号:WO2019180185A1
公开(公告)日:2019-09-26
The invention provides new heterocyclic compounds having the general formula (Ic) wherein A, L, X, m, n and R20 to R23 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.